Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + Metformin Initial Therapy in T2D
NCT00327015Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started May 2006; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00327015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327015.